CST, 95093S, Pan-Keratin (Type II) (F6G1P) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying K5 mouse/K4 mouse/K6a mouse/K8 mouse/K1 mouse/K2 mouse/K7 mouse. Validated for Western Blotting,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, Pan-Keratin (Type II) (F6G1P) Rabbit Monoclonal Antibody (CST #95093) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunohistochemistry (Paraffin): 1:800 - 1:3200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunohistochemistry (Paraffin) Specificity / Sensitivity Pan-Keratin (Type II) (F6G1P) Rabbit mAb recognizes endogenous levels of total type II keratin proteins, including keratin-1, -5, -6A, -7, and -8. This antibody also detects the type I keratin, keratin-17, and weakly detects keratin-10 and -14. Non-specific staining was observed in mouse pancreatic islets and in multinucleated giant cells of mouse spleen by immunohistochemistry. Species Reactivity: Human, Mouse, Rat Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val206 of mouse keratin 1 protein, a region that is conserved in other type II keratins. Background Keratins (cytokeratins) are intermediate filament proteins that are mainly expressed in epithelial cells. Keratin heterodimers composed of an acidic keratin (or type I keratin, keratins K9-K28) and a basic keratin (or type II keratin, keratins K1-K8 and K71-K80) assemble to form filaments. Keratin isoforms demonstrate tissue- and differentiation-specific profiles that make them useful as research and clinical biomarkers (1,2). Dysregulation/mutations in keratin genes can lead to a variety of disorders affecting the skin, hair, nails, and other epithelial tissues (3). While expression of keratins can be variable, immunohistochemical staining of keratins is widely used to help in the identification and classification of epithelial tumors, and may also provide prognostic information. Keratins 8 and 18 (K8/K18) are expressed in simple epithelia of normal tissue, as well as in adenocarcinomas of the breast, lung, ovary, and gastrointestinal tract. Keratin 17 is expressed in basal keratinocytes of stratified epithelia, hair follicles, and sebaceous glands. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development (4). Keratin 14 (K14) is expressed in basal cells of stratified epithelia, and in basal-like subtypes of breast cancer and squamous cell carcinomas. Keratin 19 (K19) is expressed in glandular epithelia, including the liver, gallbladder, and pancreas, as well as in adenocarcinomas of the breast, thyroid, and bile duct. Keratin 20 (K20) is expressed in gastrointestinal epithelium, urothelium, and Merkel cells in the skin, as well as in colorectal carcinomas and some urothelial carcinomas. Keratin 5/6 (K5/6) is expressed in basal cells of stratified epithelia, including the skin, prostate, and breast, as well as in basal-like breast cancers, squamous cell carcinomas, and some lung carcinomas. Keratin 7 (K7) is expressed in glandular epithelia, such as those in the lung, breast, and female reproductive tract, as well as in adenocarcinomas of the lung, breast, and ovary (5,6). Keratins, particularly K8, K18, and K19, serve as biomarkers for identification of circulating tumor cells (CTCs) (5). Post-translational modifications, including phosphorylation, acetylation, ubiquitylation, sumoylation, glycosylation, and transamidation, have been shown to affect the functions of keratins in normal and disease states (6). Understanding the molecular mechanisms underlying these PTMs may provide insights into cancer pathogenesis. Alternate Names 2310016L08Rik; 3300001P10Rik; 57kd keratin; 57kDa keratin; 58 kDa cytokeratin; 60-kDa keratin; 67 kDa cytokeratin; AA960620; AL022697; AU019895; AW108092; AW146334; BB005427; Car; Card2; CK-1; CK-2e; CK-4; CK-5; CK-6A; CK-7; CK-8; CK5; cytokeratin 5; Cytokeratin 7; cytokeratin 8; Cytokeratin endo A; Cytokeratin-1; Cytokeratin-2e; Cytokeratin-4; Cytokeratin-5; Cytokeratin-6A; Cytokeratin-7; Cytokeratin-8; Cytoskeletal 57 kDa keratin; D15Wsu77; D15Wsu77e; EndoA; Epithelial keratin-2e; K1; K2; K22E; K2C1; K2C4; K2C5; K2C6A; K2C7; K2C8; K2e; K4; K5; K6-alpha; K6[a]; K6A; K7; K8; Ker2; keratin 1; keratin 2; keratin 2 epidermis; keratin 4; keratin 5; keratin 6A; keratin 7; keratin 8; keratin 86; keratin complex 2, basic, gene 1; keratin complex 2, basic, gene 17; keratin complex 2, basic, gene 4; keratin complex 2, basic, gene 5; keratin complex 2, basic, gene 6a; keratin complex 2, basic, gene 6c; keratin complex 2, basic, gene 7; keratin complex 2, basic, gene 8; keratin complex 2, gene 17; keratin complex 2, gene 6a; Keratin-1; Keratin-2 epidermis; Keratin-2e; Keratin-4; Keratin-5; Keratin-6-alpha; Keratin-6A; Keratin-7; Keratin-8; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; Keratin, type II cytoskeletal 4; Keratin, type II cytoskeletal 5; Keratin, type II cytoskeletal 6A; Keratin, type II cytoskeletal 7; Keratin, type II cytoskeletal 8; Krt-2.; Krt-2.1; Krt-2.4; Krt-2.8; Krt1; Krt2; Krt2-; Krt2-1; Krt2-17; Krt2-2; Krt2-4; Krt2-5; Krt2-6; Krt2-6a; Krt2-6c; Krt2-7; Krt2-8; Krt2a; Krt2e; Krt4; Krt5; Krt6; Krt6a; Krt7; Krt8; Krt86; MGC11625; MGC118110; MK6; mK6-alpha; mK6[a; mK6[a]; MK6a; sarcolectin; Tfi; Tfip8; tuftelin interacting protein 8; Type-II keratin Kb1; Type-II keratin Kb2; Type-II keratin Kb4; Type-II keratin Kb5; Type-II keratin Kb7; Type-II keratin Kb8 Specification REACTIVITY: H M R SENSITIVITY: Endogenous MW (kDa): 45-65 Source/Isotype: Rabbit IgG